Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Molecular chirality tools for the study of Gluten Immunogenic Peptides and Celiac Disease: Novel therapeutic and diagnostic approaches.

Descrizione del progetto

Nuovi strumenti molecolari per lo studio della celiachia

La celiachia è una condizione autoimmune scatenata dal glutine presente nel grano, nell’orzo e nella segale. Data l’alta prevalenza della malattia in Europa, sono necessari trattamenti mirati che vadano oltre la dieta priva di glutine e strumenti diagnostici migliori. Finanziato dal programma di azioni Marie Skłodowska-Curie, il progetto GLUCHIRAL studia come i peptidi immunogeni del glutine (GIP) attraversano l’intestino tenue. I ricercatori intendono sviluppare inibitori peptidici contro i GIP per bloccarne gli effetti nocivi e sviluppare nuovi trattamenti contro la celiachia. Allo stesso tempo, il progetto aumenterà la consapevolezza della celiachia e delle patologie associate al glutine.

Obiettivo

Celiac disease (CD) is a systemic autoimmune disorder triggered by gluten consumption in genetically predisposed individuals, affecting a substantial portion of the European population (1.4%). A significant number of CD cases remain undiagnosed (75%), leading to untreated disease and its associated symptoms. These range from immediate gastrointestinal and extra-intestinal distress to long-term complications such as osteoporosis, infertility, and cancer, among others, placing substantial strain on society and healthcare systems. As the primary treatment for CD remains a strict gluten-free diet, there is a pressing need for innovative approaches to alleviate the burden of inadvertent gluten exposure. This proposal aims to investigate the molecular mechanisms governing the transport of gluten immunogenic peptides (GIP) across the small intestine and to develop a chiral-based strategy for the design of enantiomeric peptides that can inhibit GIP toxicity and immunogenicity. Our objectives are: 1) To develop a focused library of enantiomeric peptide inhibitors of GIP that could be used as novel therapeutic agents for CD. 2) To elucidate the molecular mechanisms of GIP transport and immunogenicity across the small intestine using GIP enantiomers as probes. 3) To establish a liquid chromatography–mass spectrometry (LC-MS) assay for GIP quantitation in biological samples as a novel diagnostic tool for assessing gut permeability in CD patients. The successful accomplishment of these objectives will provide valuable insights into GIP activity and transport within intestinal epithelium and immune cells. Moreover, it offers the potential to identify novel peptide-based therapeutics against GIP, with the possibility of further commercialization. Lastly, the success of this proposal carries the critical importance of raising awareness about CD and pathologies associated with gluten consumption, addressing the alarming rate of undiagnosed cases within the European population.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

UNIVERSIDAD DE SEVILLA
Contributo netto dell'UE
€ 226 441,20
Indirizzo
CALLE S. FERNANDO 4
41004 Sevilla
Spagna
Regione
Sur Andalucía Sevilla
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partner (1)